spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Cancer immunotherapy with the help of CAR-T cells

PlasmidFactory GmbH & Co. KG

Sleeping Beauty Minicircles enable production of CAR-T cells

Bielefeld, October 2017 – PlasmidFactory, the leading contract manufacturer for plasmid and minicircle (MC) DNA, once again highlights the cooperation with the University Hospital of Würzburg and the MD-CEL – Helmholtz Innovation Lab at the Max Delbrück Centre (MDC) Berlin in the area of cancer immunotherapy. This cancer therapy uses CAR-T cells that recognise and destroy cancer cells. The patient’s own immune cells are removed, genetically modified, and then re-introduced into the body. In conventional immunotherapies, which have shown remarkable efficacy in clinical trials, T cells are modified by retroviral vectors. However, the potential for insertional mutagenesis and genotoxicity of viral vectors poses a safety risk, and the cost and regulatory requirements will stand in the way of a fast and broad clinical application. In late August, the first CAR-T cell therapy for acute lymphoblastic leukaemia (ALL) was approved in the US.

Unlike this therapy, the genetically modified CAR-T cells are produced in a virus-free method based on Sleeping Beauty Minicircle in cooperation with PlasmidFactory. The Sleeping Beauty (SB) system includes a transposon, which is used in gene and cell therapy, in order to introduce therapeutic sequences into the genome of patient cells. Through chromosomal integration, these sequences are firmly anchored there and used, for example, to complement the genetic characteristics or to make the cell identifiable.

“In collaboration with the University Hospital of Würzburg and the MD-CEL, we have created an opportunity for the MC-based SB transposition of chimeric antigen receptor (CAR) transgenes using this innovative system. Because of the rapid production of CAR-T cells for clinical use, this allows an improved transposition compared with conventional plasmids,” explains PlasmidFactory’s Managing Director, Dr Martin Schleef.

Minicircles are small, circular DNA molecules that contain almost only the desired expression cassette. Because of the missing bacterial backbone, minicircles have now become established as alternative vectors for the transfection of eukaryotic cells. The modification of cells based on minicircle technology is combined with a transposon system. By including a transposition cassette on a minicircle, higher transposition rates of the desired gene segment can be achieved than with conventional vectors. Such minicircle-based therapies also promise a lower safety risk.

About PlasmidFactory
PlasmidFactory GmbH & Co. KG is a biopharmaceutical company founded in 2000 in Bielefeld. It has since developed into an international company. In addition to custom manufacturing of plasmid and minicircle DNA, PlasmidFactory focuses its research and development efforts on its core competencies in the production, analysis, application, and storage of plasmid and minicircle DNA.

Minicircle DNA contains effectively only the gene of interest (GOI). Unnecessary sequences used only for the production process of plasmids such as antibiotic resistance genes or the origin of replication (ori) were almost completely removed. The result is a safe and highly-effective vector system. It already meets the future regulatory requirements for gene therapy and vaccination.

Media Contact
Tatjana Buchholz
Marketing Manager, M.Sc.
T.: +49 521 299 7350
E.: info@plasmidfactory.com
Web: PlasmidFactory.com
phone +49 (0) 521 299 735 0
email info@plasmidfactory.com
web www.plasmidfactory.com
email Meisenstraße 96, D-33607 Bielefeld, Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Countdown to the UK’s leading production line event begins

In light of Nick Peters’, author of the Annual Manufacturing report 2018, comment that “UK manufacturing has come a long way in recent years, as we have seen from their stellar performance in 2017,” it’s no surprise that the PPMA Show is gearing up for its biggest show to date when it returns to the NEC, Birmingham, between 25-27 September 2018.
More info >>


White Papers

Nasal Drug Delivery with a Focus on Chronic Rhino-Sinusitis

Aptar Pharma

Aptar Pharma have hosted a scientific roundtable on “Nasal drug delivery with a focus on chronic rhino‑sinusitis”. This international scientific forum was held in Paris, France on November 13th 2012. The roundtable was organized to explore and exchange views on the science of various forms of sinusitis and its related unmet medical needs.
More info >>

Industry Events

Adaptive Designs in Clinical Trials

9-10 April 2018, Copthorne Tara Hotel, Scarsdale Place, Kensington, London, UK

Now running for 10 years, SMi’s annual conference on Adaptive Designs in Clinical Trials will return to London on 9thand 10th April 2018. This year’s agenda has been curated to provide you with the latest innovations, regulatory updates, and strategies on how industry and clinical experts are currently using adaptive designs in their clinical trials for successful drug, medical device and therapy development.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement